Cunjing Yu

Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells

R. Weller, S. Howie, J. Schwarze, 2016, The Journal of allergy and clinical immunology.

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Y. Shu, M. Dvorkin, Jie-Xie Wang, 2022 .

Nitric oxide induces human CLA+CD25+Foxp3+ regulatory T cells with skin-homing potential.

R. Weller, S. Howie, M. Norval, 2017, The Journal of allergy and clinical immunology.

Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell–IL-22 axis

R. Maizels, P. Ghazal, R. Weller, 2016, Science.

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.

Ying Cheng, Y. Shu, M. Dvorkin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Modulation of immune responses by UV irradiation

Cunjing Yu, 2016 .

Prostaglandin E2 stimulates adaptive IL‐22 production and promotes allergic contact dermatitis

R. Weller, S. Narumiya, S. Howie, 2018, The Journal of allergy and clinical immunology.

Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC

Ying Cheng, Yunpeng Liu, Y. Shu, 2021, Clinical Trials.

Targeted protein degrader development for cancer: advances, challenges, and opportunities.

Shuhang Wang, Yuan Fang, Ning Li, 2023, Trends in pharmacological sciences.